20-F: Nano-X Imaging Ltd. Files 20-F Report, Highlights FDA Clearances and Global Expansion

Nano-X Imaging Ltd. reports its fiscal year 2024 results, showcasing FDA clearances for its Nanox.ARC system and strategic moves towards global commercialization.

Summary

• Nano-X Imaging Ltd. (NNOX) has filed its Form 20-F for the fiscal year ended December 31, 2024.
• The company highlights FDA 510(k) clearances for the Nanox.ARC system, including general use for musculoskeletal, pulmonary, intra-abdominal, and paranasal sinus indications.
• A CE mark certification was received to market the multi-source Nanox.ARC system in Europe.
• The company is focused on transitioning to preventive healthcare with affordable medical imaging technologies.
• Nanox is pursuing three business models: Subscription (MSaaS), CapEx (sales), and Licensing for OEM.
• As of December 31, 2024, the company had cash, cash equivalents, short-term and long-term deposits, restricted deposits and marketable securities of $83.5 million.
• The company believes its cash on hand is sufficient to fund operations for at least the next twelve months.
• Net losses for 2024 were approximately $53.5 million.
• The company has 165 employees as of December 31, 2024.
• The company is involved in ongoing military conflicts in Israel, which could affect operations.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive developments such as FDA clearances and global expansion efforts, the company's financial performance is concerning due to ongoing net losses and the need for additional financing. The risks associated with the company's operations and the competitive landscape also contribute to a neutral sentiment.

Positives

• FDA clearance for general use of Nanox.ARC expands potential applications.
• CE mark certification opens access to the European market.
• The company has a strong cash position to fund operations in the near term.
• The company is actively pursuing strategic collaborations and partnerships.
• The company is developing new AI-based features to enhance the images generated by the Nanox System.

Negatives

• The company has a history of net losses and negative cash flow from operations.
• The company is in the initial stages of commercial deployment of the Nanox System.
• The company is subject to risks associated with the ongoing military conflicts in Israel.
• The company is subject to risks associated with regulation of new and emerging technologies such as artificial intelligence.
• The company may be classified as a passive foreign investment company (PFIC) for U.S. federal income tax purposes.

Risks

• The company may not be able to successfully execute its business models.
• The company may need to obtain additional financing to fund its future operations.
• The company's industry is highly competitive and is subject to technological change.
• The company expects to depend on third parties to manufacture the Nanox.ARC and to supply certain component parts.
• The company could become subject to product liability claims, product recalls, warranty claims and professional malpractice liability claims.
• The mishandling or the perceived mishandling of sensitive information, or the occurrence of data security breaches, could harm the company's business.
• Conditions in Israel could materially and adversely affect the company's business.

Future Outlook

The company anticipates continued expenses related to the development and commercialization of its products and expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic partnerships, or marketing, distribution or licensing arrangements with third parties.

Industry Context

The medical imaging market is expected to grow, driven by the increasing use of advanced AI-enabled diagnostic equipment. Nanox aims to disrupt the market by providing more accessible and affordable medical imaging solutions.

Comparison to Industry Standards

• The document mentions competitors such as GE Healthcare, Siemens, Philips, Hologic, Varian, Fuji, Toshiba and Hitachi.
• The document states that there are over 700 FDA cleared AI products in the imaging field and mentions Aidoc Medical Ltd. as a competitor offering various solutions.
• The document states that the teleradiology market is highly competitive and mentions StatRad, ONRAD and Radiology Partners as principal competitors.

Legal Proceedings

• The Company paid a civil penalty in the amount of $650,000 and was permanently enjoined from violating Section 17(a)(2) of the Securities Act and Section 13(a) of the Securities Exchange and Rules 12b-20 and 13a-1 thereunder.
• In February 2025, the radiologists defendants and USARAD entered into a formal settlement agreement with the plaintiff to settle the complaint for $20,000 each.

Stakeholder Impact

• Shareholders face risks related to potential dilution from future equity offerings and the volatility of the share price.
• Employees may be affected by changes in the company's operations and financial performance.
• Customers and patients may benefit from increased access to affordable medical imaging technologies.
• Suppliers and creditors may be impacted by the company's ability to meet its financial obligations.

Next Steps

• The company plans to seek additional clearances or approvals for additional uses of the currently cleared Nanox System, or for future versions of the Nanox System.
• The company is in the process of expanding a U.S.-based sales and service team that will seek to generate leads, close sales, manage relationships, and provide services for the Nanox System installed base.

Key Dates

Keywords

Nanox, medical imaging, FDA clearance, CE mark, Nanox.ARC, Nanox.CLOUD, AI, teleradiology, MSaaS, X-ray, healthcare